• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Oculis Holding AG

    3/4/26 4:31:29 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    6-K 1 ocs_6-k_ifrssfs_2025.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of March 2026

    (Commission File No. 001-41636)

     

     

    Oculis Holding AG

    (Translation of registrant's name into English)

     

     

    Bahnhofstrasse 20

    CH-6300

    Zug, Switzerland

    (Address of registrant’s principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒

    Form 40-F ☐

     

     

     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Financial Statements

     

    Oculis Holding AG's (the “Registrant”) 2025 IFRS consolidated financial statements and 2025 Statutory Financial Statements are furnished as Exhibits 99.1 and 99.2, respectively, to this Report on Form 6-K.

     

    Renewal of ATM Program

     

    On March 4, 2026, in connection with filing a new Registration Statement on Form F-3, the Company entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Leerink Partners, LLC (“Leerink Partners”) with respect to its existing at-the-market offering program (the “ATM Program”). As originally disclosed in May 2024, under the ATM Program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The issuance and sale, if any, of the ordinary shares by the Company under the Sales Agreement will be made pursuant to the Company’s effective registration statement on Form F-3 filed with the Securities and Exchange Commission on March 4, 2026 (File No. 333-294011) (the “Registration Statement”).

     

    The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 to this report on Form 6-K and is incorporated herein by reference. A copy of the legal opinion of VISCHER AG, the Company’s Swiss counsel, relating to the underlying shares to be issued in connection with the Sales Agreement was filed as Exhibit 5.1 to the Registration Statement. This report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

     

    Incorporation by Reference

     

    This Report on Form 6-K, including Exhibits 1.1, 99.1 and 99.2, is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-271938 and 333-287806) and Form F-3 (File Nos. 333-294011, 333-278409, 333-271063 and 333-291426).

     

    EXHIBIT INDEX

     

    Exhibit

    Description

    1.1

     

    Amended and Restated Sales Agreement, dated as of March 4, 2026, by and between Oculis Holding AG and Leerink Partners, LLC

    99.1

     

    IFRS consolidated financial statements as of and for the year ended December 31, 2025

    99.2

     

    Statutory Financial Statements of Oculis Holding AG for the year ended December 31, 2025

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

    OCULIS HOLDING AG

     

     

     

     

    Date: March 4, 2026

     

    By:

    /s/ Sylvia Cheung

     

     

     

    Chief Financial Officer

     


    Get the next $OCS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/19/2025$38.00Overweight
    Analyst
    8/27/2025$36.00Buy
    Needham
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    More analyst ratings

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Oculis Holding AG with a new price target

    Analyst initiated coverage of Oculis Holding AG with a rating of Overweight and set a new price target of $38.00

    12/19/25 8:50:10 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Oculis Holding AG with a new price target

    Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00

    8/27/25 8:25:52 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

    Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

    12/5/23 8:03:01 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    SEC Filings

    View All

    SEC Form 6-K filed by Oculis Holding AG

    6-K - Oculis Holding AG (0001953530) (Filer)

    3/4/26 4:31:29 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3ASR filed by Oculis Holding AG

    F-3ASR - Oculis Holding AG (0001953530) (Filer)

    3/4/26 4:19:03 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Oculis Holding AG

    20-F - Oculis Holding AG (0001953530) (Filer)

    3/4/26 4:01:28 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oculis to Participate in Upcoming Investor Conferences

    ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in upcoming investor conferences in March. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) granted breakthrough therapy designation for optic neuritis (ON

    3/5/26 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

    Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029 ZUG, Switzerland, March 3, 2026 -- Oculis Holding AG (NASDAQ:OCS) (Oculis), a global biopharmace

    3/3/26 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Appoints Katie Kazem as Chief Legal Officer

    Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis' le

    2/17/26 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oculis Holding AG

    SC 13G - Oculis Holding AG (0001953530) (Subject)

    12/9/24 9:43:55 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

    SC 13G/A - Oculis Holding AG (0001953530) (Subject)

    11/7/24 4:15:49 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Appoints Katie Kazem as Chief Legal Officer

    Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis' le

    2/17/26 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

    Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company f

    8/25/25 4:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Publishes Invitation to the Annual General Meeting

    ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

    5/9/25 4:05:00 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCS
    Financials

    Live finance-specific insights

    View All

    Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

    Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha

    10/6/25 4:07:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

    DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

    5/22/23 6:30:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

    ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

    4/4/23 7:00:00 AM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care